ASCO Abstracts Highlight Late-stage Sanofi Oncology Pipeline - Progress on Jevtana®, Zaltrap™ and JAK2 inhibitor featured
Sanofi (EURONEXT: SAN and NYSE: SNY) announced today abstracts spanning the company’s innovative marketed and late-stage development compounds will be featured at the 2012 American Society of Clinical Oncology Annual Meeting in Chicago, Ill., June 1-5. Sanofi products are noted in more than 170 abstracts to be presented at the meeting.